Management and ownership · SANA PHARMA HOLDING AS
Group
Subsidiaries
- HETE INVEST AS 100%NOK 5.2m
- IMMUNOCORP CONSUMER HEALTH AS 100%
- SANA PHARMA MANAGEMENT AS 91%
Employees in the group: 0
The bar is the company's latest operating revenue, the percentage the parent's share. Source: the Tax Administration's Register of Shareholders, read 31 Jul 2026 Employees and revenue from the Register of Legal Entities and the Register of Company Accounts.
The group's revenue
- SANA PHARMA HOLDING AS
- The rest of the group, assumed
The group 2020: operating revenue NOK 225.9m (+44.3%), net profit NOK 104.3m, equity NOK 533.3m. SANA PHARMA HOLDING AS accounts for NOK 917k of the revenue; the rest, an assumed NOK 225.0m, is in the subsidiaries.
Assumed: the group figures are after the elimination of internal transactions, so the rest is an estimate. Source: the Register of Company Accounts, read 9 Nov 2026 · See the whole group accounts 2018–2020 →
Roles across the group
1 of the 4 people with roles in the group holds a role in more than one of its companies.
| Person | Roles in the group |
|---|---|
| Morten Brennesvik-Jensen | Board member SANA PHARMA MANAGEMENT AS, Deputy board member IMMUNOCORP CONSUMER HEALTH AS |
Source: the Register of Legal Entities, fetched —